Market Cap 21.22M
Revenue (ttm) 0.00
Net Income (ttm) -9.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 127,900
Avg Vol 247,808
Day's Range N/A - N/A
Shares Out 21.60M
Stochastic %K 40%
Beta 1.30
Analysts Strong Sell
Price Target $6.50

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gumm...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 937 6137
Address:
1 Controls Drive, Shelton, United States
STRAYNUT
STRAYNUT Apr. 10 at 10:07 PM
$NNVC Short Interest (03/31/26) Shares Sold Short 756,215 Change from Last -6.07% Percent of Float 3.60% https://www.wsj.com/market-data/quotes/NNVC
0 · Reply
STRAYNUT
STRAYNUT Apr. 10 at 12:07 AM
$NNVC NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to announce that the company has filed an application for Rare Pediatric Disease Drug Designation with the U.S. FDA’s Office of Orphan Products Development for NV-387 as a treatment for measles.https://finance.yahoo.com/video/nanoviricides-files-rare-pediatric-disease-152434012.html WATCH THIS!
0 · Reply
drkazmd65
drkazmd65 Apr. 8 at 1:51 PM
$NNVC - Here's hoping for an update on how dosing for treating monkey pox is going for Phase 2a by about early May. I don't expect them to show the results until they have them all together, but just an update on how the patient pool is filling. If the PR was correct, then the CRO should have started training the on-site medical staff by now.
0 · Reply
STRAYNUT
STRAYNUT Apr. 7 at 6:45 PM
$NNVC Study the chronology of events in early February, 2026: 3. Now fast-forward to today's PR: a. NNVC has filed an application for RPDD designation as a treatment for measles and it is expected to be joined together with the earlier ODD application. Upon approval NNVC will be eligible for a Priority Review Voucher (PRV) which carries the benefit of accelerated approval and thereby can be sold to a Big Pharma (BPh) for around $160 MILLION in a bidding process. CONCLUSION: With a market cap of only $23 million ($1.07), just think what $160 million+/- would do to the stock price!!!
1 · Reply
STRAYNUT
STRAYNUT Apr. 7 at 6:43 PM
$NNVC: Study the chronology of events in early February, 2026: 1. On February 3rd, the Rare Pediatric Disease Drug (RPDD) Priority Review Voucher program was reauthorized by Congress and signed into Law by president Trump. 2. On February 10th, NNVC filed an application with the US FDA for Orphan Drug Designation (ODD) for NV-387 as a treatment for measles, using the expert services of Dr Timothy Cote of Only Orphans Cote, LLC, a regulatory consulting firm. There is no approved drug for the treatment of measles, and Dr. Diwan further states that NV-387 is the ONLY drug candidate he knows of that "has demonstrated strong in vivo activity against lethal infection with the Measles virus in a humanized animal model study".
0 · Reply
STRAYNUT
STRAYNUT Apr. 7 at 12:55 PM
$NNVC Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/measles-rare-pediatric-disease-drug-designation-application-filed-for-1155499
0 · Reply
STRAYNUT
STRAYNUT Apr. 3 at 6:58 PM
$NNVC A Slam-Dunk in the Offing: The Upcoming Phase II MPOX Clade I Human Trial (hMPXL) in the DRC Explained The Oral Gummies bister (a pre-formed plastic cavity) pack will be used in the trial, due to patients having difficulty swallowing with Clade I, a more severe strain of the human monkeypoxvirus that is endemic in the DRC (Democratic Republic of Congo). The blister cap is carefully removed and the dose is carefully placed on the tongue and allowed to melt. The normal dosing is once a day for 6 days.The patient is counseled to take no water and be sure not to swallow it. The Phase I trial in India proved that NV-387 is absolutely safe and well-tolerated, but the 2a trial in the Congo will stop after 6 days to confirm that data. The 2b randomized trial involving 60 patients will last 28 days with the efficacy outcomes being complete lesion recovery, elimination of new rash formation, and a measure of viral load.https://www.nanoviricides.com/files/News%20PDFs/Zacks_SCR_Research_11062025_NNVC_Bautz.pdf
0 · Reply
Love1010
Love1010 Apr. 3 at 4:48 PM
$NNVC @drkazmd65 Straynut is a bit of a jerk I would say. Always blaming others for his pathetic investments. Making arrogant promises that don't come true. Talk about "high and mighty"
1 · Reply
STRAYNUT
STRAYNUT Apr. 1 at 6:12 PM
$NNVC Responding to drkazmd65: I vividly remember you from a casual conversation we had in the lunchroom when "whale" investors were invited to the lab for a conference room session with Dr. Diwan and a complete tour of the lab itself. I immediately realized you were a complete fraud, in that your moniker states you are a medical doctor, when you were only a lab technician. Furthermore, you told me the number of shares you then owned, which I remember as 3500, a paltry number indeed. Readers of this board should not accord you any credibility, especially considering your "high and mighty attitude."
1 · Reply
drkazmd65
drkazmd65 Apr. 1 at 3:42 PM
$NNVC - So, CRO-directed staff training is expected to start in the DRC during the first week of April. That's a positive sign for once. The CRO is apparently going to be a CRO from India. I assume it is going to be the same one that ran the Phase I trial that only used healthy patients in the mix. So hopefully they know what they are doing already. Damn,... Diwan might finally generate some data.
0 · Reply
Latest News on NNVC
NanoViricides, Inc. Has Filed its Annual Report

Sep 30, 2025, 8:45 AM EDT - 6 months ago

NanoViricides, Inc. Has Filed its Annual Report


NanoViricides Measles Drug Development Animal Study is Imminent

Jun 4, 2025, 6:55 AM EDT - 11 months ago

NanoViricides Measles Drug Development Animal Study is Imminent


NanoViricides, Inc. Has Filed its Quarterly Report

Feb 19, 2025, 6:30 AM EST - 1 year ago

NanoViricides, Inc. Has Filed its Quarterly Report


NanoViricides Engages CRO for Phase II Clinical Trial

Jan 27, 2025, 6:30 AM EST - 1 year ago

NanoViricides Engages CRO for Phase II Clinical Trial


STRAYNUT
STRAYNUT Apr. 10 at 10:07 PM
$NNVC Short Interest (03/31/26) Shares Sold Short 756,215 Change from Last -6.07% Percent of Float 3.60% https://www.wsj.com/market-data/quotes/NNVC
0 · Reply
STRAYNUT
STRAYNUT Apr. 10 at 12:07 AM
$NNVC NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to announce that the company has filed an application for Rare Pediatric Disease Drug Designation with the U.S. FDA’s Office of Orphan Products Development for NV-387 as a treatment for measles.https://finance.yahoo.com/video/nanoviricides-files-rare-pediatric-disease-152434012.html WATCH THIS!
0 · Reply
drkazmd65
drkazmd65 Apr. 8 at 1:51 PM
$NNVC - Here's hoping for an update on how dosing for treating monkey pox is going for Phase 2a by about early May. I don't expect them to show the results until they have them all together, but just an update on how the patient pool is filling. If the PR was correct, then the CRO should have started training the on-site medical staff by now.
0 · Reply
STRAYNUT
STRAYNUT Apr. 7 at 6:45 PM
$NNVC Study the chronology of events in early February, 2026: 3. Now fast-forward to today's PR: a. NNVC has filed an application for RPDD designation as a treatment for measles and it is expected to be joined together with the earlier ODD application. Upon approval NNVC will be eligible for a Priority Review Voucher (PRV) which carries the benefit of accelerated approval and thereby can be sold to a Big Pharma (BPh) for around $160 MILLION in a bidding process. CONCLUSION: With a market cap of only $23 million ($1.07), just think what $160 million+/- would do to the stock price!!!
1 · Reply
STRAYNUT
STRAYNUT Apr. 7 at 6:43 PM
$NNVC: Study the chronology of events in early February, 2026: 1. On February 3rd, the Rare Pediatric Disease Drug (RPDD) Priority Review Voucher program was reauthorized by Congress and signed into Law by president Trump. 2. On February 10th, NNVC filed an application with the US FDA for Orphan Drug Designation (ODD) for NV-387 as a treatment for measles, using the expert services of Dr Timothy Cote of Only Orphans Cote, LLC, a regulatory consulting firm. There is no approved drug for the treatment of measles, and Dr. Diwan further states that NV-387 is the ONLY drug candidate he knows of that "has demonstrated strong in vivo activity against lethal infection with the Measles virus in a humanized animal model study".
0 · Reply
STRAYNUT
STRAYNUT Apr. 7 at 12:55 PM
$NNVC Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/measles-rare-pediatric-disease-drug-designation-application-filed-for-1155499
0 · Reply
STRAYNUT
STRAYNUT Apr. 3 at 6:58 PM
$NNVC A Slam-Dunk in the Offing: The Upcoming Phase II MPOX Clade I Human Trial (hMPXL) in the DRC Explained The Oral Gummies bister (a pre-formed plastic cavity) pack will be used in the trial, due to patients having difficulty swallowing with Clade I, a more severe strain of the human monkeypoxvirus that is endemic in the DRC (Democratic Republic of Congo). The blister cap is carefully removed and the dose is carefully placed on the tongue and allowed to melt. The normal dosing is once a day for 6 days.The patient is counseled to take no water and be sure not to swallow it. The Phase I trial in India proved that NV-387 is absolutely safe and well-tolerated, but the 2a trial in the Congo will stop after 6 days to confirm that data. The 2b randomized trial involving 60 patients will last 28 days with the efficacy outcomes being complete lesion recovery, elimination of new rash formation, and a measure of viral load.https://www.nanoviricides.com/files/News%20PDFs/Zacks_SCR_Research_11062025_NNVC_Bautz.pdf
0 · Reply
Love1010
Love1010 Apr. 3 at 4:48 PM
$NNVC @drkazmd65 Straynut is a bit of a jerk I would say. Always blaming others for his pathetic investments. Making arrogant promises that don't come true. Talk about "high and mighty"
1 · Reply
STRAYNUT
STRAYNUT Apr. 1 at 6:12 PM
$NNVC Responding to drkazmd65: I vividly remember you from a casual conversation we had in the lunchroom when "whale" investors were invited to the lab for a conference room session with Dr. Diwan and a complete tour of the lab itself. I immediately realized you were a complete fraud, in that your moniker states you are a medical doctor, when you were only a lab technician. Furthermore, you told me the number of shares you then owned, which I remember as 3500, a paltry number indeed. Readers of this board should not accord you any credibility, especially considering your "high and mighty attitude."
1 · Reply
drkazmd65
drkazmd65 Apr. 1 at 3:42 PM
$NNVC - So, CRO-directed staff training is expected to start in the DRC during the first week of April. That's a positive sign for once. The CRO is apparently going to be a CRO from India. I assume it is going to be the same one that ran the Phase I trial that only used healthy patients in the mix. So hopefully they know what they are doing already. Damn,... Diwan might finally generate some data.
0 · Reply
STRAYNUT
STRAYNUT Apr. 1 at 3:11 PM
$NNVC NanoViricides to begin Phase II trial of MPox treatment in Congo Proactive https://finance.yahoo.com/sectors/healthcare/articles/nanoviricides-begin-phase-ii-trial-131500334.html
0 · Reply
Mobler12
Mobler12 Mar. 30 at 9:15 PM
$NNVC So the most shorts can make is $20M. I really don't see the upside (profitwise) for the shorts. That's why I conclude that this stock is being manipulated big time. Only deep pockets will accept a risk/loss like that and call it good.
0 · Reply
Love1010
Love1010 Mar. 30 at 9:09 PM
$NNVC damaged beyond repair
0 · Reply
Love1010
Love1010 Mar. 30 at 6:36 PM
$NNVC @SBCatcher about this dude @straynut check his past calls in this stock and his investment in CODX. This guy is clueless. Claims short cabals are manipulating when management for both companies are incompetent. Avoid him.
0 · Reply
STRAYNUT
STRAYNUT Mar. 30 at 10:22 AM
$NNVC: The absurdity of Nano's valuation is further exemplified by noting the Enterprise Value of only $14.43 million, defined as Market Capitalization ($19.58 million) + Debt ( zero) - Cash ($5.0 million from secondary offering from Armistice Capital on 11-10-2025).
0 · Reply
STRAYNUT
STRAYNUT Mar. 29 at 10:29 PM
$NNVC: Replying to SBCatcher, who plaintively asks innocently about any thoughts: YOU BET WE HAVE. You will never again see a more undervalued company, selling for a mere $20 million valuation with a technology that will essentially CURE all viruses - past - present - and future ---- without even entering a human cell to do so. Dr. Diwan has worked a total of 34 YEARS on his invention of the "nano (small) viri (virus) cides (killers)" and we investors have expensed $170 MILLION during his 21 year public iteration, now awaiting results from the Congo Phase II trial of mpox. That imminent success will VALIDATE the entire suite of target viruses: COVID, Long COVID, measles, smallpox, RSV, Influenza etc, with the overall market size estimated to be well in excess of $10 BILLION. Can you now understand our excitement?
1 · Reply
SBCatcher
SBCatcher Mar. 27 at 3:33 PM
$NNVC what are thoughts here?
2 · Reply
7FigureTrades
7FigureTrades Mar. 24 at 11:07 PM
$NNVC believe what I have is enough
0 · Reply
STRAYNUT
STRAYNUT Mar. 24 at 10:36 PM
$NNVC Short Interest (03/13/26) Shares Sold Short 805,111 Change from Last -16.39% Percent of Float 3.83% https://www.wsj.com/market-data/quotes/NNVC
0 · Reply
jcooptechit
jcooptechit Mar. 20 at 7:57 PM
$NNVC EXPANDS PIPELINE AND FDA ORPHAN DRUG PLAY IN MOTION 🧬 NanoViricides recently filed for FDA Orphan Drug Designation (ODD) for NV-387 targeting measles. This could be a major strategic unlock. 📊 Why this matters: ▪️ Strong in vivo results in humanized measles model ▪️ Potential for 7 YEARS market exclusivity ▪️ Tax credits + fee exemptions = reduced costs, higher upside ▪️ Rising measles cases highlight urgent need for treatment ▪️ NV-387 advancing toward Phase II across multiple viral indications 💡 If ODD is granted, it could significantly de-risk development + enhance commercial potential. Is NNVC building a sleeper biotech story before the crowd catches on? Communicated - Disclaimer: https://fh.bio/jcoop
1 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 7:14 PM
$NNVC : Early Reversal Setup? 📊 NanoViricides continues advancing its antiviral platform targeting multiple virus families, while the chart is sitting near a key support zone that could determine the next move. Technical view: 1️⃣ Major support: ~$0.95–$1.05 zone 2️⃣ Price stabilizing after a prolonged downtrend, with signs of base formation 3️⃣ Recent spike in volume + failed breakdown hints at potential accumulation Reclaim levels to watch: 🔼 $1.28 first resistance area (near-term pivot) 🔼 $1.50–$1.68 next supply zone 🔼 $2.03–$2.24 key breakout range Fundamental backdrop: 🔹 Developing broad-spectrum antiviral therapies 🔹 Proprietary nanomedicine platform targeting viruses directly 🔹 Positioned in the high demand infectious disease space Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $NVAX $ADMA $VXRT $ALT
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 6:30 PM
$NNVC : From Manufacturing to Clinical Execution NanoViricides has completed manufacturing of its NV-387 oral drug, a key step ahead of Phase 2 trials. With production in place, the company is preparing to enter clinical-stage testing, initially focused on Mpox. NV-387 is part of a broad-spectrum antiviral platform targeting multiple viruses, including coronaviruses, influenza, and RSV. Key implications: 🟰Removes a major manufacturing hurdle 🟰Enables progression into Phase 2 trials 🟰Supports a multi-indication platform strategy What to watch: 🟰Phase 2 initiation and data 🟰Clinical efficacy signals 🟰 Expansion into additional viral targets NNVC remains early-stage, but this milestone marks a clear step toward unlocking the platform’s broader potential. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply